Jill Wahleithner worked as a research scientist in both industry and academia for 10 years before moving to the financial industry as a biotech consultant. Since 2004, she has focused on reviewing the science of emerging biotechs for equity investment firms. In 2006, she signed an exclusive contract with Wasatch Advisors, and in 2014 transitioned to a full-time employee of Wasatch, where she helps company portfolio managers navigate the complex world of biotech.
"INO's idea of using DNA, which is simple to make and cost-effective, to drive the body's natural immune response is just fascinating."
The Life Sciences Report Interview with Jill Wahleithner